Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • COVID-19
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • Topics A-Z
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

June 16, 2020; 94 (24) Resident & Fellow Section

Pearls and Oy-sters: Vitamin B6 deficiency presenting with new-onset epilepsy and status epilepticus in a patient with Parkinson disease

Joseph S. Modica, Deana Bonno, View ORCID ProfileKarlo J. Lizarraga
First published May 28, 2020, DOI: https://doi.org/10.1212/WNL.0000000000009647
Joseph S. Modica
From the Department of Neurology (J.S.M., D.B., K.J.L.) and Motor Physiology and Neuromodulation Program (K.J.L.), Division of Movement Disorders and Center for Health + Technology, Department of Neurology, University of Rochester, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deana Bonno
From the Department of Neurology (J.S.M., D.B., K.J.L.) and Motor Physiology and Neuromodulation Program (K.J.L.), Division of Movement Disorders and Center for Health + Technology, Department of Neurology, University of Rochester, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karlo J. Lizarraga
From the Department of Neurology (J.S.M., D.B., K.J.L.) and Motor Physiology and Neuromodulation Program (K.J.L.), Division of Movement Disorders and Center for Health + Technology, Department of Neurology, University of Rochester, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Karlo J. Lizarraga
Full PDF
Citation
Pearls and Oy-sters: Vitamin B6 deficiency presenting with new-onset epilepsy and status epilepticus in a patient with Parkinson disease
Joseph S. Modica, Deana Bonno, Karlo J. Lizarraga
Neurology Jun 2020, 94 (24) e2605-e2607; DOI: 10.1212/WNL.0000000000009647

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1228

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Article Figures & Data

Figures

  • Tables
  • Figure
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure Scalp EEG recording examples in this patient with Parkinson disease and pyridoxine deficiency causing new-onset epilepsy and status epilepticus

    Frequent, independent, multifocal epileptiform discharges (arrows) are shown with maximal amplitudes on the (A and C) right frontal (Fp2 electrode), (A and C) left frontotemporal (FT9 electrode), (B and D) midline (Fz/Cz electrodes), and (B and D) right frontotemporal regions (FT10/F8 electrodes). EEG activity was recorded with scalp electrodes positioned according to the 10–20 international system. Signals from (A and B) average referential and (C and D) bipolar montages were recorded at a sample rate of 500 Hz, sensitivity of 7 μV/mm, high-frequency filter of 70 Hz, and low-frequency filter of 1 Hz. Panels A (average referential montage) and C (bipolar montage) correspond to the same time epoch. Panels B (average referential montage) and D (bipolar montage) correspond to the same time epoch.

Tables

  • Figures
  • Table1
  1. Joseph S. Modica, MD,
  2. Deana Bonno, MD and
  3. Karlo J. Lizarraga, MD, MSc
  1. From the Department of Neurology (J.S.M., D.B., K.J.L.) and Motor Physiology and Neuromodulation Program (K.J.L.), Division of Movement Disorders and Center for Health + Technology, Department of Neurology, University of Rochester, NY.
  1. Correspondence
    Dr. Lizarraga karlo.lizarraga{at}gmail.com
Scientific Advisory Boards:
  1. NONE

Gifts:
  1. NONE

Funding for Travel or Speaker Honoraria:
  1. NONE

Editorial Boards:
  1. NONE

Patents:
  1. NONE

Publishing Royalties:
  1. NONE

Employment, Commercial Entity:
  1. NONE

Consultancies:
  1. NONE

Speakers' Bureaus:
  1. NONE

Other Activities:
  1. NONE

Clinical Procedures or Imaging Studies:
  1. NONE

Research Support, Commercial Entities:
  1. NONE

Research Support, Government Entities:
  1. NONE

Research Support, Academic Entities:
  1. NONE

Research Support, Foundations and Societies:
  1. NONE

Stock/Stock Options/Board of Directors Compensation:
  1. NONE

License Fee Payments, Technology or Inventions:
  1. NONE

Royalty Payments, Technology or Inventions:
  1. NONE

Stock/Stock Options, Research Sponsor:
  1. NONE

Stock/Stock Options, Medical Equipment & Materials:
  1. NONE

Legal Proceedings:
  1. NONE

Scientific Advisory Boards:
  1. NONE

Gifts:
  1. NONE

Funding for Travel or Speaker Honoraria:
  1. NONE

Editorial Boards:
  1. NONE

Patents:
  1. NONE

Publishing Royalties:
  1. NONE

Employment, Commercial Entity:
  1. NONE

Consultancies:
  1. NONE

Speakers' Bureaus:
  1. NONE

Other Activities:
  1. NONE

Clinical Procedures or Imaging Studies:
  1. NONE

Research Support, Commercial Entities:
  1. NONE

Research Support, Government Entities:
  1. NONE

Research Support, Academic Entities:
  1. NONE

Research Support, Foundations and Societies:
  1. NONE

Stock/Stock Options/Board of Directors Compensation:
  1. NONE

License Fee Payments, Technology or Inventions:
  1. NONE

Royalty Payments, Technology or Inventions:
  1. NONE

Stock/Stock Options, Research Sponsor:
  1. NONE

Stock/Stock Options, Medical Equipment & Materials:
  1. NONE

Legal Proceedings:
  1. NONE

Scientific Advisory Boards:
  1. NONE

Gifts:
  1. NONE

Funding for Travel or Speaker Honoraria:
  1. NONE

Editorial Boards:
  1. (1) Brain & Life en Español (AAN journal), Editorial Board, 2017-Present, no compensation. (2) Surgical Neurology International - Stereotactic, Editorial Board, 2017-Present, no compensation.

Patents:
  1. NONE

Publishing Royalties:
  1. NONE

Employment, Commercial Entity:
  1. NONE

Consultancies:
  1. NONE

Speakers' Bureaus:
  1. NONE

Other activities:
  1. (1) Non-profit entity: Founder and director of "La Escuelita AQMED" in Peru. This local entity provides supplementary medical education in Arequipa, Peru.

Clinical Procedures or Imaging Studies:
  1. NONE

Research Support, Commercial Entities:
  1. NONE

Research Support, Government Entities:
  1. NONE

Research Support, Academic Entities:
  1. NONE

Research Support, Foundations and Societies:
  1. (1) Movement Disorders Fellowship Grant from the Dystonia Medical Research Foundation Canada (2018-2019).

Stock/Stock Options/Board of Directors Compensation:
  1. NONE

License Fee Payments, Technology or Inventions:
  1. NONE

Royalty Payments, Technology or Inventions:
  1. NONE

Stock/Stock Options, Research Sponsor:
  1. NONE

Stock/Stock Options, Medical Equipment & Materials:
  1. NONE

Legal Proceedings:
  1. NONE

Graphic

Pearls

  • Pyridoxine (vitamin B6) deficiency is a treatable cause of new-onset epilepsy and status epilepticus in patients with Parkinson disease (PD).

  • Long-standing high-dose carbidopa-levodopa intake in the setting of gastroparesis or poor nutritional intake may contribute to pyridoxine deficiency in patients with PD.

Oy-sters

  • Unrecognized pyridoxine deficiency in patients with PD could lead to epilepsy and status epilepticus.

  • There is no evidence to support dietary avoidance of pyridoxine in patients with PD who are treated with carbidopa-levodopa.

Case report

An 83-year-old woman with hypertension, coronary artery disease, and PD developed recurring paroxysmal events consistent with multifocal motor and nonmotor epileptic seizures with and without secondary generalization. Repeated EEG studies revealed multifocal epileptiform discharges or electrographic seizures. Brain MRI and CSF studies were unremarkable.

Over the next 6 months, her epileptic seizures became progressively more frequent despite treatment with oral levetiracetam (1,000 mg twice daily, 29.45 mg/kg/d), topiramate (100 mg twice daily, 2.95 mg/kg/d), phenytoin (150 mg twice daily, 4.42 mg/kg/d), and lorazepam (0.5 mg daily). She presented to the emergency department at our institution after several recurrent seizures without return to her neurologic baseline. Despite initial administration of 2 mg IV lorazepam, the patient had 1 additional focal motor seizure requiring 2 more mg of IV lorazepam. Her levetiracetam dose was increased to 1,500 mg twice daily (44 mg/kg/d) after a loading IV dose of 1,000 mg. Clinical seizures ceased, but she required intubation for airway protection. Her health care proxy agreed to intubation despite a previous advanced directive given the potential reversibility of her current condition. Despite her antiepileptic medication levels being therapeutic, continuous video-EEG monitoring persistently showed occasional electrographic seizures and frequent multifocal epileptiform discharges (figure).

Figure
Figure Scalp EEG recording examples in this patient with Parkinson disease and pyridoxine deficiency causing new-onset epilepsy and status epilepticus

Frequent, independent, multifocal epileptiform discharges (arrows) are shown with maximal amplitudes on the (A and C) right frontal (Fp2 electrode), (A and C) left frontotemporal (FT9 electrode), (B and D) midline (Fz/Cz electrodes), and (B and D) right frontotemporal regions (FT10/F8 electrodes). EEG activity was recorded with scalp electrodes positioned according to the 10–20 international system. Signals from (A and B) average referential and (C and D) bipolar montages were recorded at a sample rate of 500 Hz, sensitivity of 7 μV/mm, high-frequency filter of 70 Hz, and low-frequency filter of 1 Hz. Panels A (average referential montage) and C (bipolar montage) correspond to the same time epoch. Panels B (average referential montage) and D (bipolar montage) correspond to the same time epoch.

Her dopaminergic regimen for PD treatment had remained stable for the previous 2 years. Her medications included 1 tablet of carbidopa/levodopa 25/100 mg controlled release and 2 tablets of carbidopa/levodopa 25/100 mg immediate release taken together 7 times per day (2,100 mg/d), pramipexole 1.5 mg per mouth 3 times daily, and amantadine 100 mg per mouth daily. Her total levodopa-equivalent daily dose was 2,475 mg. According to her health care proxy, the patient had developed progressively worsening symptoms consistent with gastroparesis and unintended weight loss of 9 kg over the 6 months before seizure onset. Furthermore, the proxy reported that she had been specifically trying to avoid pyridoxine (vitamin B6) in her diet after learning about the potential reduction of levodopa efficacy in a support group. Unfortunately, the patient and her health care proxy had not discussed this decision with any of her physicians.

Laboratory studies confirmed the suspicion of pyridoxine deficiency. She had very low serum pyridoxine (<5 nmol/L, normal 20–125 nmol/L), low serum folate (4.2 ng/mL, normal >4.6 ng/mL), normal serum vitamin B12 (1,060 pg/mL, normal 232–1,245 pg/mL), and high serum homocysteine (19 μmol/L, normal 0–15 μmol/L) levels. Pyridoxine replacement was started at 20 mg/d IV with immediate improvement in her mental status, resolution of electrographic seizures, and marked reduction in the frequency of epileptiform discharges. Unfortunately, the patient did not tolerate extubation due to severe laryngeal stenosis and, along with her health care proxy, decided not to be reintubated, subsequently passing away.

Discussion

Pyridoxine deficiency is thought to cause epilepsy due to decreased production of gamma-aminobutyric acid, the main inhibitory neurotransmitter in the brain. Pyridoxine deficiency is a well-known etiology of intractable epileptic seizures and status epilepticus in neonates and children. However, it has rarely been reported and may be underdiagnosed as a cause of epileptic seizures in adults.1,2

Pyridoxine is required as a cofactor for the metabolism of levodopa into dopamine and can theoretically be depleted by excessive amounts of levodopa.3 In fact, a dose-dependent association has been reported in which levodopa-equivalent daily doses of ≥2,000 mg result in pyridoxine deficiency in virtually all patients, regardless of the levodopa formulation and route of administration.4 Indeed, the prevalence of peripheral neuropathy associated with reduced levels of vitamins B6 and B12 is higher in patients treated with oral (30.2%) or intestinal (42.1%) formulations of levodopa compared to people of a similar age (8%–10%).5

For unknown reasons, the 1% prevalence of epilepsy in noninstitutionalized elderly people increases to 8.3% in those who live with PD in nursing homes.6 High-dose carbidopa-levodopa treatment as a jejunal gel infusion has previously been reported to cause marked pyridoxine deficiency and epileptic seizures that resolved after pyridoxine supplementation in 1 patient with PD.7 The patient we report developed new-onset treatment-resistant multifocal epilepsy and status epilepticus due to multifactorial pyridoxine deficiency, including treatment with oral levodopa. She was consistently taking levodopa-equivalent daily doses >2,000 mg/d for at least 2 years in the setting of poor nutritional intake, weight loss, and avoidance of supplementary dietary pyridoxine. Although early research suggested that pyridoxine might accelerate the metabolism and reduce the effectiveness of levodopa in the treatment of PD,8 further studies suggested that carbidopa prevented this theoretical reduction of levodopa effects and recommended against dietary avoidance of pyridoxine.9,–,11 Moreover, vitamin B6 and B12 supplementation has been recommended for patients with PD who have peripheral neuropathy symptoms or supportive biochemical alterations.5 Timely recognition and treatment of pyridoxine deficiency could prevent new-onset epileptic seizures and status epilepticus in patients with PD treated with high-dose levodopa.

Study funding

No targeted funding reported.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Appendix Authors

Table

Footnotes

  • Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

  • © 2020 American Academy of Neurology

References

  1. 1.↵
    1. Tong Y
    . Seizures caused by pyridoxine (vitamin B6) deficiency in adults: a case report and literature review. Intractable Rare Dis Res 2014;3:52–56.
    OpenUrl
  2. 2.↵
    1. Plecko B,
    2. Stöckler S
    . Vitamin B6 dependent seizures. Can J Neurol Sci 2009;36(suppl 2):S73–S77.
    OpenUrlPubMed
  3. 3.↵
    1. Sourkes TL
    . Dopa decarboxylase: substrates, coenzyme, inhibitors. Pharmacol Rev 1966;18:53–60.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Loens S,
    2. Chorbadzhieva E,
    3. Kleimann A,
    4. Dressler D,
    5. Schrader C
    . Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy. Brain Behav 2017;7:e00698.
    OpenUrl
  5. 5.↵
    1. Romagnolo A,
    2. Merola A,
    3. Artusi CA,
    4. Rizzone MG,
    5. Zibetti M,
    6. Lopiano L
    . Levodopa-induced neuropathy: a systematic review. Mov Disord Clin Pract 2018;6:96–103.
    OpenUrl
  6. 6.↵
    1. Birnbaum AK,
    2. Leppik IE,
    3. Svensden K,
    4. Eberly LE
    . Prevalence of epilepsy/seizures as a comorbidity of neurologic disorders in nursing homes. Neurology 2017;88:750–757.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Skodda S,
    2. Müller T
    . Refractory epileptic seizures due to vitamin B6 deficiency in a patient with Parkinson's disease under duodopa therapy. J Neural Transm 2013;120:315–318.
    OpenUrl
  8. 8.↵
    1. Leon AS,
    2. Spiegel HE,
    3. Thomas G,
    4. Abrams WB
    . Pyridoxine antagonism of levodopa in parkinsonism. JAMA 1971;218:1924–1927.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Yahr MD,
    2. Duvoisin RC
    . Pyridoxine and levodopa in the treatment of Parkinsonism. JAMA 1972;220:861. Letter.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Mars H
    . Levodopa, carbidopa, and pyridoxine in Parkinson disease: metabolic interactions. Arch Neurol 1974;30:444–447.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Pinder RM,
    2. Brogden RN,
    3. Sawyer PR,
    4. Speight TM,
    5. Avery GS
    . Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism. Drugs 1976;11:329–377.
    OpenUrlPubMedWeb of Science

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Pearls
    • Oy-sters
    • Case report
    • Discussion
    • Study funding
    • Disclosure
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

  • Parkinson's disease/Parkinsonism
  • Nutritional
  • Status epilepticus

Alert Me

  • Alert me when eletters are published
Neurology: 98 (21)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise